SFM
RARX

Sphera Funds Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Sphera Funds Management’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-60,000
Closed -$1.28M – 145
2017
Q1 		$1.28M Hold
60,000
– – 0.25% 89
2016
Q4 		$911K Buy
+60,000
New +$816K 0.23% 85

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sphera Funds Management's RARX Position: Q2 2017 in Review

Sphera Funds Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2017, closing a stake of 60,000 shares — an estimated $1.28M sold.

Sphera Funds Management first reported a position in RARX in Q4 2016 and held it in 2 quarters. The position peaked at $1.28M in Q1 2017. 65 funds tracked by Wall St. Rank hold RARX as of Q2 2017.

  • Sphera Funds Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Sphera Funds Management sold 60,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2017, an estimated $1.28M.
  • Sphera Funds Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
  • Sphera Funds Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $1.28M in Q1 2017.
  • 65 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2017.

Based on Sphera Funds Management's 13F filing for Q2 2017, filed 9 Aug 2017.